Vaccine

Johnson & Johnson Single-Shot COVID-19 Vaccine Candidate Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee

Friday, February 26, 2021 - 10:43pm

The next step in the process is for the FDA to decide whether to grant an EUA for Janssen's COVID-19 vaccine candidate.

Key Points: 
  • The next step in the process is for the FDA to decide whether to grant an EUA for Janssen's COVID-19 vaccine candidate.
  • The recommendation of the FDA Advisory Committee is non-binding, and the final decision on authorization is made by the FDA.
  • We are confident that our COVID-19 vaccine candidate will have a significant impact in protecting people around the world," said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, Johnson & Johnson.
  • The Johnson & Johnson COVID-19 single-dose vaccine candidate is compatible with standard vaccine storage and distribution channels with ease of delivery to remote areas.

AARP Members Frustrated with Pennsylvania's COVID-19 Vaccine Distribution Efforts, Survey Shows

Friday, February 26, 2021 - 9:10pm

HARRISBURG, Pa., Feb. 26, 2021 /PRNewswire/ -- Older adults are frustrated and angry with Pennsylvania's distribution of COVID-19 vaccines to date, according to a survey of AARP members statewide.

Key Points: 
  • HARRISBURG, Pa., Feb. 26, 2021 /PRNewswire/ -- Older adults are frustrated and angry with Pennsylvania's distribution of COVID-19 vaccines to date, according to a survey of AARP members statewide.
  • Some 3,465 AARP members from across Pennsylvania responded to the informal survey, which showed that while 81 percent of respondents tried to secure a vaccine appointment, only 27 percent were successful so far.
  • Johnston-Walsh said the stories from AARP members demonstrate how the vaccine distribution plan isfragmented, hard to navigate, and is leaving behind many of the state's most vulnerable and at risk populations.
  • AARP also produces the nation's largest circulation publications: AARP The Magazine and AARP Bulletin.

Worldwide Foot and Mouth Disease Vaccine Industry to 2026 - Players Include Agrovet, Bayer and Biogenesis Bago Among Others

Friday, February 26, 2021 - 2:45pm

The global foot and mouth disease (FMD) vaccine market grew at a CAGR of around 6% during 2015-2020.

Key Points: 
  • The global foot and mouth disease (FMD) vaccine market grew at a CAGR of around 6% during 2015-2020.
  • The foot and mouth disease (FMD) occurs due to a transboundary, contagious virus that infects cloven-hoofed animals.
  • Looking forward, the publisher expects the global foot and mouth disease (FMD) vaccine market to continue its moderate growth during the next five years.
  • What is the structure of the global foot and mouth disease (FMD) market and who are the key players?

Rational Vaccines names Dr. Konstantin Kousoulas Vice President of Scientific Affairs

Friday, February 26, 2021 - 2:00pm

CAMBRIDGE, Mass., Feb. 26, 2021 /PRNewswire/ --Leading virologist Konstantin "Gus" Kousoulas joined Rational Vaccines as vice president of Scientific Affairs where he will work to further the company's core mission of eradicating the world of the herpes simplex virus (HSV), the company announced today.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 26, 2021 /PRNewswire/ --Leading virologist Konstantin "Gus" Kousoulas joined Rational Vaccines as vice president of Scientific Affairs where he will work to further the company's core mission of eradicating the world of the herpes simplex virus (HSV), the company announced today.
  • His addition to the team brings us one step closer to our goal of eradicating the Herpes pandemic."
  • Kousoulas' research focuses primarily on the molecular biology and the immunopathogenesis of human herpes viruses.
  • Rational Vaccines develops rationally engineered, live attenuated viral immunotherapeutic and prophylactic vaccine candidates, particularly focused on combating all diseases resulting from herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2) infections.

Novavax and Takeda Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan

Friday, February 26, 2021 - 1:22pm

The companies have signed an exclusive license agreement for Takedas development, manufacturing and commercialization of NVX-CoV2373, Novavax COVID-19 vaccine candidate, in Japan.

Key Points: 
  • The companies have signed an exclusive license agreement for Takedas development, manufacturing and commercialization of NVX-CoV2373, Novavax COVID-19 vaccine candidate, in Japan.
  • Additionally, Takeda dosed the first participants in a Phase 2 clinical trial to test the immunogenicity and safety of Novavax vaccine candidate in the Japanese population.
  • This agreement progresses our collaboration with Takeda as we rapidly work together to make our vaccine candidate available in Japan, said Stanley C. Erck, President and Chief Executive Officer of Novavax.
  • Novavax will transfer the technology for manufacturing of the vaccine antigen and will supply its Matrix-M adjuvant to Takeda.

Celsion Corporation to Participate in the Virtual 33ʳᵈ Annual Roth Conference

Friday, February 26, 2021 - 1:45pm

LAWRENCEVILLE, N.J., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today announced that management will be holding one-on-one meetings with investors during the Virtual 33rd Annual Roth Conference, being held March 15 17, 2021.

Key Points: 
  • LAWRENCEVILLE, N.J., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today announced that management will be holding one-on-one meetings with investors during the Virtual 33rd Annual Roth Conference, being held March 15 17, 2021.
  • A webcast of Celsions presentation will be pre-recorded and will be available on the Companys website during the week before the conference.
  • Institutional and other investors interested in meeting with Celsion during the conference should contact their Roth Capital Partners sales representative or LHA Investor Relations.
  • Celsion also has two feasibility stage platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies.

Schedule Your COVID-19 Vaccine at Golden Valley Memorial Healthcare

Friday, February 26, 2021 - 1:00pm

Golden Valley Memorial Healthcare (GVMH) is currently scheduling COVID-19 vaccine appointments at its Clinton, Osceola, Warsaw and Windsor facilities.

Key Points: 
  • Golden Valley Memorial Healthcare (GVMH) is currently scheduling COVID-19 vaccine appointments at its Clinton, Osceola, Warsaw and Windsor facilities.
  • To schedule an appointment for the COVID-19 vaccine, please call 660.324.2995.
  • This number is the only way to schedule a vaccine at GVMH.
  • Golden Valley Memorial Healthcare (GVMH) is a leading rural healthcare organization dedicated to providing compassionate, friendly, quality care for patients close to home.

European Medicines Agency Accepts Pfizer’s Marketing Authorization Application for Its Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age or Older

Friday, February 26, 2021 - 11:45am

The epidemiology of pneumococcal serotypes causing disease has been changing due to the success of pneumococcal conjugate vaccines targeting pediatric and adult populations.

Key Points: 
  • The epidemiology of pneumococcal serotypes causing disease has been changing due to the success of pneumococcal conjugate vaccines targeting pediatric and adult populations.
  • In June 2020 Pfizer announced initiation of two Phase three trials for 20vPnC evaluating the safety and efficacy of the investigational vaccine in infants.
  • Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance.
  • Prevention of Antibiotic-Nonsusceptible Invasive Pneumococcal Disease With the 13-Valent Pneumococcal Conjugate Vaccine.

Statement of the members of the European Council on COVID-19 and health, 25 February 2021

Friday, February 26, 2021 - 8:01am

We are determined to continue to work together and coordinate our action to tackle the pandemic and its consequences.

Key Points: 
  • We are determined to continue to work together and coordinate our action to tackle the pandemic and its consequences.
  • We must therefore uphold tight restrictions while stepping up efforts to accelerate the provision of vaccines.
  • The unhindered flow of goods and services within the Single Market must be ensured, including by making use of Green Lanes.
  • Even so, we need to urgently accelerate the authorisation, production and distribution of vaccines, as well as vaccination.
  • We call for work to continue on a common approach to vaccination certificates and will come back to this issue.
  • We reaffirm our solidarity with third countries and underline our determination to step up our global response to the pandemic.
  • We will continue to keep the overall situation under close review and take action as needed.

II. HEALTH

    • Although the COVID-19 crisis is not yet over, it is time to start strengthening our future health resilience now.
    • We will work to improve EU coordination, in line with the Union competences under the Treaties, to ensure better prevention, preparedness for and response to future health emergencies.
    • Work on the Health Union proposals and on the Pharmaceutical Strategy, including as regards access to medicines across Member States, should also be taken forward.
    • We are committed to advancing global health security, including by strengthening the World Health Organization and working towards an international treaty on pandemics within its framework.
    • In this context, we look forward to the G20 Global Health Summit in Rome.

Remarks by President Charles Michel following the first session of the video conference of the members of the European Council

Friday, February 26, 2021 - 8:00am

We also discussed the lessons learned from this crisis to strengthen our health systems and improve our EU coordination.

Key Points: 
  • We also discussed the lessons learned from this crisis to strengthen our health systems and improve our EU coordination.
  • VaccinationsOur top priority now is speeding up the production and delivery of vaccines, and vaccinations, across the EU.
  • Thats why we support the Commissions efforts to work with industry to identify bottlenecks, guarantee supply chains, and scale up production.
  • And we want more predictability and transparency to ensure that pharmaceutical companies comply with their commitments.
  • Thats why enhancing our sequencing capacity is key to these efforts.And we need to continue to invest in vaccine research to update our vaccines.
  • More work needs to be done - on digitalisation and on cooperation with the World Health Organisation.
  • But tonight we felt more and more convergence among us on this important topic.The European Council will revert to this matter.
  • Our help should go to all those in need, including in Africa, Western Balkans, Eastern Partnership and Latin America.
  • Je voudrais adresser maintenant quelques commentaires sur la situation dans laquelle nous nous trouvons sur le terrain de la lutte contre le COVID-19.
  • Finally one word on Russia: we will have a strategic debate in March on our relationship with Russia.